Teva Pharmaceutical Industries (TEVA) Receiving Somewhat Positive Media Coverage, Report Shows

News articles about Teva Pharmaceutical Industries (NYSE:TEVA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.661599071876 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Several brokerages have issued reports on TEVA. Cantor Fitzgerald set a $18.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, May 17th. Zacks Investment Research raised Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, May 9th. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, May 7th. Morgan Stanley reaffirmed a “hold” rating and set a $18.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, May 7th. Finally, Credit Suisse Group set a $23.00 price target on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, May 14th. Ten analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $19.82.

Shares of NYSE TEVA traded up $0.15 during mid-day trading on Wednesday, reaching $21.15. The company had a trading volume of 9,772,658 shares, compared to its average volume of 14,507,918. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.65 and a current ratio of 1.00. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $33.82. The stock has a market capitalization of $21.45 billion, a P/E ratio of 5.38, a PEG ratio of 1.72 and a beta of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, May 3rd. The company reported $0.91 EPS for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.28. Teva Pharmaceutical Industries had a positive return on equity of 18.59% and a negative net margin of 72.36%. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.80 billion. During the same quarter last year, the business earned $1.06 earnings per share. Teva Pharmaceutical Industries’s revenue was down 10.0% on a year-over-year basis. equities research analysts forecast that Teva Pharmaceutical Industries will post 2.45 earnings per share for the current year.

In related news, Director Roberto Mignone purchased 750,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 10th. The shares were bought at an average price of $19.24 per share, for a total transaction of $14,430,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 5,684 shares of company stock worth $105,411 in the last 90 days. 0.43% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with's FREE daily email newsletter.

Leave a Reply